BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
High cholesterol / dyslipidemia clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for hypercholesterolemia: 70 (34 sponsors; 15 newly posted in the last 180 days, 2 stopped in the last 180 days; 6 new-entrant sponsors). Momentum score 32.9, rank 3 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 0, Phase 1 9, Phase 2 9, Phase 3 30, Phase 4 4, N/A 18.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Novartis Pharmaceuticals NVS | 13 | NA 5, P4 1, P3 6, P2 1 | 1 | 5 |
| AstraZeneca AZN | 4 | P3 4 | 3 | 1 |
| Merck Sharp & Dohme LLC MRK | 4 | P3 4 | 1 | 0 |
| Qilu Pharmaceutical Co., Ltd. | 5 | P3 3, P1 1, P2 1 | 0 | 0 |
| CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | 4 | P3 3, P2 1 | 0 | 0 |
| Arrowhead Pharmaceuticals ARWR | 2 | P3 2 | 0 | 0 |
| LIB Therapeutics LLC | 2 | P3 2 | 1 | 0 |
| Beijing Suncadia Pharmaceuticals Co., Ltd | 2 | P2 1, P3 1 | 0 | 0 |
| Daiichi Sankyo | 2 | P3 1, NA 1 | 0 | 0 |
| Hasten Biopharmaceutical Co., Ltd. | 2 | P1 1, P3 1 | 0 | 0 |
| A. Menarini International Licensing S.A. new entrant | 1 | P3 1 | 1 | 1 |
| Hyundai Pharm | 1 | P3 1 | 0 | 0 |
| Visirna Therapeutics HK Limited | 1 | P3 1 | 0 | 0 |
| Eli Lilly and Company LLY | 4 | NA 1, P1 2, P2 1 | 1 | 0 |
| Boryung Pharmaceutical Co., Ltd | 2 | NA 2 | 1 | 0 |
| Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | 2 | NA 2 | 0 | 0 |
| Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2 | P1 2 | 1 | 0 |
| Addpharma Inc. | 1 | P1 1 | 0 | 0 |
| Ahn-Gook Pharmaceuticals Co.,Ltd | 1 | NA 1 | 0 | 0 |
| Amgen AMGN new entrant | 1 | P4 1 | 1 | 0 |
| CRISPR Therapeutics AG CRSP | 1 | P1 1 | 0 | 0 |
| Eddingpharm (Zhuhai) Co., Ltd. | 1 | P2 1 | 0 | 0 |
| Editas Medicine, Inc. EDIT new entrant | 1 | P2 1 | 1 | 0 |
| ESI new entrant | 1 | NA 1 | 1 | 0 |
| Hangzhou Dinovate Biotech Co., Ltd | 1 | P2 1 | 0 | 0 |
New-entrant sponsors: A. Menarini International Licensing S.A., Amgen, Editas Medicine, Inc., ESI.
Recently stopped trials
- NCT06789432 Dr. Md. Alimur Reza - withdrawn: Withdrawn by the sponsor before any participant was enrolled. Protocol-specified screening and randomization were not initiated at the study Efficacy and Safety of Atorvastatin and Ezetimibe (10/10mg) Fixed Dose Combination Versus Atorvastatin (20mg) Monotherap
- NCT05217667 Arrowhead Pharmaceuticals - terminated: Business decision, unrelated to safety concerns. Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH)
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12-12 est. | P2 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | NCT07729475 A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral SAL0137 in Adults With Elevated Lp(a) and Increased Risk of Cardiovascular Events | Elevated Lipoprotein(a) | not yet recruiting | 120 |
| 2026-12-29 est. | P2 | Regeneron Pharmaceuticals REGN | NCT07477704 A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia | Hypercholesterolemia | active not recruiting | 438 |
| 2026-12-31 est. | P2 | MediciNova MNOV | NCT05464784 MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia | Diabetes Mellitus, Type 2; Hypertriglyceridemia; Non-Alcoholic Fatty Liver Disease | active not recruiting | 40 |
| 2027-01 est. | P3 | A. Menarini International Licensing S.A. | NCT07614958 Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs Bempedoic Acid to Treat Dyslipidemia in Adults With Primary Non-familial | Mixed Dyslipidemia; Hypercholesterolaemia | recruiting | 426 |
| 2027-01-04 est. | P3 | AstraZeneca AZN | NCT07000136 A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH | Heterozygous Familial Hypercholesterolaemia | active not recruiting | 473 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-04 est. | P3 | CMG Pharmaceutical Co. Ltd | NCT06772168 Evaluate the Efficacy and Safety of CMG190303 in Patients With Type 2 Diabetes and Dyslipidemia | Dyslipidemia; Type 2 Diabetes | recruiting | 240 |
| 2026-11 est. | P2 | NewAmsterdam Pharma NAMS | NCT06496243 Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels | Dyslipidemias | recruiting | 69 |
| 2026-10-04 est. | P2 | Eddingpharm (Zhuhai) Co., Ltd. | NCT07489209 A Dose-exploration Study of EDP167 in HoFH | Homozygous Familial Hypercholesterolemia (HoFH) | recruiting | 20 |
| 2026-09-03 | P2 | AstraZeneca AZN | NCT07218900 A Study to Investigate the Effect of AZD0780 Tablets in Combination With Rosuvastatin Tablets on Low Density Lipoprotein Cholesterol Levels (LDL-C) in Adult Par | Dyslipidaemia | completed | 76 |
| 2026-09 est. | P2 | Fujian Shengdi Pharmaceutical Co., Ltd. | NCT07100418 A Clinical Study Evaluating the Efficacy and Safety of HRS-7249 in Treating Patients With Hyperlipidemia | Hyperlipidemia | active not recruiting | 224 |
| 2026-08-26 | P3 | Innovent Biologics (Suzhou) Co. Ltd. | NCT07473960 IBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia | Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia | completed | 198 |
| 2026-08-03 | P3 | Merck Sharp & Dohme LLC MRK | NCT07216482 A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037) | Hyperlipidemia | completed | 996 |
| 2026-08 est. | P2 | Shandong Suncadia Medicine Co., Ltd. | NCT07229937 A Phase II Study To Evaluate the Efficacy And Safety Of HRS-1301 In Participants With Dyslipidemia | Hyperlipidemia | recruiting | 189 |
| 2026-07-31 est. | P1/P2 | Shanghai JMT-Bio Inc. | NCT07140809 a Phase 1b/2a Study of JMT202 Injection in Participants With Hypertriglyceridemia | Hypertriglyceridemia | recruiting | 48 |
| 2026-07-16 | P3 | Novartis Pharmaceuticals NVS | NCT04023552 Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD | Cardiovascular Disease and Lipoprotein(a) | completed | 8323 |
| 2026-07 est. | P2 | Marea Therapeutics | NCT07199309 A Mechanistic Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol | Hypertriglyceridemia | recruiting | 30 |
| 2026-06-30 est. | P2 | Shanghai Argo Biopharmaceutical Co., Ltd. | NCT06497127 A Study in Patients With Mixed Dyslipidemia | Mixed Dyslipidemia | active not recruiting | 145 |
| 2026-06-17 | P3 | Arrowhead Pharmaceuticals ARWR | NCT06347016 Study of Plozasiran in Adults With Severe Hypertriglyceridemia | Severe Hypertriglyceridemia | completed | 311 |
| 2026-06-12 | P3 | Arrowhead Pharmaceuticals ARWR | NCT06347003 Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia | Severe Hypertriglyceridemia | completed | 446 |
| 2026-06-03 est. | P1/P2 | Ikaria Bioscience Pty Ltd | NCT06471543 Study of RN0361in Adult Healthy Subjects and Adult Hypertriglyceridemic Subjects | Hypertriglyceridemia; Familial Chylomicronemia Syndrome | active not recruiting | 108 |
| 2026-06-01 | P3 | Arrowhead Pharmaceuticals ARWR | NCT06347133 Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia | Hypertriglyceridemia | completed | 1456 |
| 2026-06 est. | P2 | Qilu Pharmaceutical Co., Ltd. | NCT06750341 Study of QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyperlipidemia With Elevated LDL Cholesterol | Primary Hypercholesterolemia or Mixed Hyperlipidemia | not yet recruiting | 156 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "hypercholesterolemia"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.